[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aadi Bioscience, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100515861","phase-2-trial-of-nab-sirolimus-in-combination-with-letrozole-in-patients-with-advanced-or-recurrent-endometrioid-endometrial-cancer-100515861",false,"NCT05997017","Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer","A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer","Inclusion Criteria:\n\n1. Patients must have clinically confirmed advanced or recurrent endometrioid endometrial carcinoma. Histologic documentation of the recurrence is suggested but not required.\n2. All patients must have 1 or more measurable target lesion at baseline by computed tomography (CT; or magnetic resonance imaging \\[MRI\\] if CT scans are contraindicated) as defined by RECIST version 1.1.\n3. Patients must have EEC that is metastatic or locally advanced where surgical resection is not an option or likely to result in severe morbidity.\n4. Prior treatment history:\n\n   1. Adjuvant setting - treatment with chemotherapy, hormonal therapy,checkpoint inhibitors, and\u002For other therapy is permitted as long as theadjuvant therapy ended ≥6 months from enrollment.\n   2. Recurrent\u002Fadvanced\u002Fmetastatic setting - treatment with 0-1 prior chemotherapy regimens is permitted (patients may be naïve to chemotherapy); chemotherapy must have been completed ≥3 months prior to enrollment. Patients are permitted to have received adjuvant chemotherapy and no more than 1 line of chemotherapy in the recurrent\u002Fadvanced\u002Fmetastatic setting.\n   3. Non-chemotherapy-based treatment (eg, checkpoint inhibitors, hormonal therapy, and\u002For small molecule agents) is permitted at any point as long as therapy ended ≥4 weeks prior to enrollment.\n   4. Patients who have received prior therapy in the recurrent\u002Fadvanced\u002Fmetastatic setting must have achieved a complete or partial response(investigator-assessed) to at least 1 therapy.\n5. Age: 18 years or older.\n6. Patient must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Adequate liver function:\n\n   1. Total bilirubin ≤1.5 × upper limit of normal (ULN) (unless due to Gilbert's syndrome, then ≤3 × ULN)\n   2. Aspartate aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases)\n8. Adequate renal function: creatinine clearance (CrCL) ≥30 mL\u002Fmin based on Cockcroft-Gault\n9. Adequate hematologic parameters:\n\n   1. Absolute neutrophil count (ANC) ≥1.0 × 109\u002FL (growth factor support allowed)\n   2. Platelet count ≥100,000\u002Fmm3 (100 × 109\u002FL) (transfusion and\u002For growth factor support allowed)\n   3. Hemoglobin ≥8.0 g\u002FdL (transfusion and\u002For growth factor support allowed)\n10. Fasting serum triglyceride must be ≤300 mg\u002FdL; fasting serum cholesterol must be less than or equal to 350 mg\u002FdL.\n11. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of prior systemic anticancer therapy, or at least 5 half-lives if the prior therapy is a single agent small-molecule therapeutic, and adequately recovered from the acute toxicities of any prior therapy, including neuropathy, to Grade ≤1.\n12. Non-pregnant and non-breastfeeding female:\n\n    1. Females of childbearing potential must agree to use effective contraception or abstinence without interruption from 28 days prior to starting nab-Sirolimus through 3 months after the last dose of nab-Sirolimus and have a negative serum pregnancy test (beta human chorionic gonadotropin \\[β-hCG\\]) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment. A second form of birth control is required even if she has had a tubal ligation.\n    2. Sexual abstinence is considered a highly effective contraceptive method only if defined as refraining from heterosexual intercourse from 28 days prior to starting study medication throughout 3 months after last dose of study medication. The reliability of sexual abstinence should be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient.\n13. The patient understands and signs the informed consent.\n14. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures.\n15. Patients with a known history of human immunodeficiency virus (HIV)infection are eligible if:\n\n    1. There has been no acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection in 12 months prior to enrollment.\n    2. The patient has been receiving an antiretroviral therapy regimen for≥4 weeks and the HIV viral load is \\\u003C400 copies\u002FmL prior to enrollment.\n    3. Antiretroviral therapy regimen does not include strong cytochrome(CYP)3A4 inhibitors or inducers\n\nExclusion Criteria:\n\n1. Prior treatment with an mTOR inhibitor, including nab-sirolimus.\n2. Patients with known inactivating TSC1 or TSC2 alterations (based on tissue or liquid next generation sequencing \\[NGS\\]) unless the PRECISION 1 study (NCT05103358) has been closed to enrollment.\n3. Severe (Grade ≥3) ongoing infection requiring parenteral or oral anti-infective treatment, either ongoing or completed ≤7 days prior to enrollment.\n4. Patients with primary refractory disease (ie, those who have never achieved a complete or partial response to prior therapy) are not permitted on study.\n5. Patients with the following are excluded:\n\n   1. Known or suspected brain metastases.\n   2. Severe heart disease defined as unstable angina pectoris, New York Heart Association (NYHA) Class III or IV congestive heart failure, myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.\n   3. Severe lung disease defined as a diffusing capacity for carbon monoxide (DLCO) that is ≤50% of normal predicted value and\u002For an O2 saturation ≤88% at rest on room air (Note: spirometry and pulmonary function tests \\[PFTs\\] are not required to be performed unless clinically indicated).\n   4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy.\n   5. A history of malignancies other than the one under treatment unless the patient is disease-free for more than 5 years from completion of therapy administered with curative intent. Controlled non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, certain low grade hematologic malignancies (eg, chronic lymphocytic leukemia \\[CLL\\], follicular lymphoma, etc), or other adequately treated carcinoma in situ may be eligible, after discussion with the Medical Monitor.\n   6. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg\n   7. Patients with history of interstitial lung disease and\u002For pneumonitis, or pulmonary hypertension.\n   8. Active hepatitis B and\u002For hepatitis C infection and detectable viral load despite antiviral therapy\n6. Required use of concomitant medications with strong CYP3A4 interactions (induction or inhibition) should be discontinued (strong inhibitors include ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, telithromycin; strong inducers include rifampin and rifabutin). These agents must be discontinued prior to first dose of nab-sirolimus.","ALL","18 Years",{"count":19,"type":20},29,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer",[26,27,28,29,30,31],"Endometrial Cancer","Endometrioid Tumor","Cancer","Tumor","Recurrent Endometrial Carcinoma","Endometrioid Endometrial Cancer",[33,34,35,36,37,38,39,27,26,30,31],"nab-Sirolimus","FYARRO","Letrozole","Endometrial","Recurrent","ABI-009","Endometrial Carcinoma","RECRUITING","2025-11-12",{"date":43,"type":44},"2025-11-13","ACTUAL",{"date":46,"type":44},"2023-12-28",{"date":48,"type":20},"2027-06",{"name":50,"class":51},"Aadi Bioscience, Inc.","INDUSTRY",9,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100490079","phase-1-dose-escalation-study-to-assess-safety-and-pharmacokinetics-of-nab-sirolimus-in-patients-with-locally-advanced-or-metastatic-solid-tumors-and-moderate-liver-impairment-100490079","NCT05661461","Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment","A Phase 1, Open-label, Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment","Inclusion Criteria:\n\n* For All Patients\n\n  1. Willing and able to provide informed consent and comply with protocol requirements for the duration of the study.\n  2. Male or female patients at least 18 years of age at the time of signing the informed consent form.\n  3. Histologically confirmed locally advanced or metastatic solid tumors that is measurable or non-measurable.\n  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.\n  5. Adequate hematologic counts:\n\n     * Absolute neutrophil count (ANC) ≥1.0 × 109 \u002FL (growth factor support allowed)\n     * Platelet count ≥75,000\u002Fmm 3 (75 × 10 9 \u002FL) (transfusion and\u002For growth factor support allowed)\n     * Hemoglobin ≥8.0 g\u002FdL (transfusion and\u002For growth factor support allowed)\n  6. Creatinine clearance ≥30 mL\u002Fmin as assessed by the Cockcroft-Gault equation:\n\n     Creatinine Clearance ≥30 = (140 - age) × (weight\\[kg\\] \u002F (72 x SCr\\[mL\u002Fmin\\]\\_ x 0.85, if female\n  7. Fasting serum triglyceride must be ≤300 mg\u002FdL; fasting serum cholesterol must be\n\n     ≤350 mg\u002FdL.\n  8. Male or non-pregnant and non-breastfeeding female:\n\n     * Females of child-bearing potential must agree to use highly effective contraception or abstinence without interruption from 28 days prior to first dose throughout 3 months after last dose and have a negative pregnancy test (urine or serum) result at screening and after the end of study treatment. A second form of birth control is required even if she has had a tubal ligation.\n     * Male patients must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after last dose. A second form of birth control is required even if he has undergone a successful vasectomy.\n  9. Minimum of 4 weeks since major surgery, completion of radiation, or completion of all prior systemic anticancer therapy, or at least 5 half-lives if the prior therapy is a single agent small-molecule therapeutic, and in either case adequately recovered from the acute toxicities of any prior therapy (including neuropathy) to Grade ≤1. For Patients with Normal Hepatic Function\n  10. Normal hepatic function (total bilirubin ≤ upper limit of normal \\[ULN\\] and aspartate aminotransferase \\[AST\\] ≤ULN). For Patients with Moderate Hepatic Impairment\n  11. Moderate hepatic impairment (total bilirubin 1.5-3.0 × ULN and any level of AST)\n\nExclusion Criteria:\n\n1. Received prior treatment with an mTOR inhibitor within 4 weeks prior to first dose.\n2. Patients who have any severe and\u002For uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including:\n\n   1. Patients with meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, untreated brain metastases or symptomatic or unstable brain metastases. Note: Patients with stable brain metastases (defined as asymptomatic or no requirement for high-dose \\[defined as dexamethasone 10 mg daily or higher\\] or increasing dose of systemic corticosteroids) and without imminent need of radiation therapy are eligible. If applicable, patients must have completed brain radiation therapy and recovered adequately from any associated toxicity and\u002For complications prior to eligibility assessment. For patients who have received prior radiation therapy, post-treatment magnetic resonance imaging (MRI) scan should show no increase in brain lesion size\u002Fvolume.\n   2. Unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association, NYHA class III or IV), myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.\n   3. Pre-existing severely impaired lung function. If a patient has a pre-existing pulmonary condition, eligible patients should have a spirometry and diffusing capacity for carbon monoxide (DLCO) that is \\>50% of the normal predicted value and\u002For O2 saturation that is \\>88% at rest on room air (Note: spirometry and pulmonary function tests \\[PFTs\\] not required to be performed unless clinically indicated).\n   4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy. Note, controlled non melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, or other adequately treated carcinoma-in-situ may be eligible, after documented discussion with the Medical Monitor.\n   5. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg).\n   6. Patients with history of interstitial lung disease and\u002For pneumonitis, or pulmonary hypertension.\n   7. Individuals with known human immunodeficiency virus (HIV) infection are excluded from this study as combination antiretroviral therapy could potentially result in significant pharmacokinetic interactions. In addition, these individuals are at increased risk of serious infections due to the immunosuppressive effects of mTOR inhibition.\n   8. Active Hepatitis B or Hepatitis C, with detectable viral load. Note: A detailed assessment of Hepatitis B\u002FC medical history and risk factors must be done at screening for all patients.\n3. Have active severe (Grade ≥3) infection requiring intravenous (IV) antibiotics (contact medical monitor for clarification).\n4. High-dose systemic corticosteroids (\\>10 mg of prednisone or its equivalent) are not permitted within 2 weeks of first dose. However, inhaled, intranasal, intra articular, and topical steroids are allowed.\n5. Have a history of Gilbert's disease.\n6. Any condition that in the opinion of the Investigator would place the patient at an unacceptable risk or cause the patient to be unlikely to fully participate or comply with study procedures.\n\n   For Patients with Moderate Hepatic Impairment\n7. Had a clinical exacerbation of liver disease within the 2-week period prior to first dose (ie, abdominal pain, nausea, vomiting, anorexia, or fever).\n8. Have clinically demonstrable, tense ascites.\n9. Had evidence of acute viral hepatitis within 1 month prior to first dose.\n10. Have evidence of hepatorenal syndrome.\n11. Have a transjugular intrahepatic portosystemic shunt.\n12. Have active stage 3 or 4 encephalopathy.",{"count":61,"type":20},28,[63],"PHASE1","This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.",[66,29,67],"Tumor, Solid","Advanced Solid Tumor",{"date":43,"type":44},{"date":70,"type":44},"2022-11-23",{"date":72,"type":20},"2026-08-01",{"name":50,"class":51},2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100515864","phase-2-trial-of-nab-sirolimus-in-patients-with-well-differentiated-neuroendocrine-tumors-nets-of-the-gastrointestinal-tract-lung-or-pancreas-who-have-not-received-prior-treatment-with-mtor-inhibitors-100515864","NCT05997056","Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors","A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors","Inclusion Criteria:\n\n1. Patients with functional or non-functional, well-differentiated, locally advanced unresectable or metastatic NETs of the GI tract, lung, or pancreas who have received 2 or less prior lines of therapy excluding somatostatin analogs\n2. Patients with functional NETs may enroll if:\n\n   1. the patient has been on a stable dose of an somatostatin analogs for ≥12 weeks and\n   2. the patient has experienced disease progression while on stable somatostatin analogs dose\n3. Patients must have 1 or more measurable target lesions by RECIST v1.1\n4. Age: 18 years or older\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or Karnofsky Performance Status (KPS) ≥80\n6. Adequate liver function:\n\n   1. Total bilirubin ≤1.5 × upper limit of normal (ULN) (unless due to Gilbert's syndrome or attributable to liver metastases, then ≤3 × ULN)\n   2. Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases)\n7. Adequate renal function: creatinine clearance ≥30 mL\u002Fmin, Cockcroft-Gault creatinine clearance = ((140-age) × weight\\[kg\\]) \u002F (72 × serum creatinine \\[mL\u002Fmin\\]) × 0.85, if female.\n8. Adequate hematologic parameters:\n\n   1. Absolute neutrophil count (ANC) ≥1.0 × 10\\^9\u002FL (growth factor support allowed)\n   2. Platelet count ≥100,000\u002Fmm\\^3 (100 × 10\\^9\u002FL) (transfusion and\u002For growth factor support allowed)\n   3. Hemoglobin ≥8.0 g\u002FdL (transfusion and\u002For growth factor support allowed)\n9. Fasting serum triglyceride must be ≤300 mg\u002FdL; fasting serum cholesterol must be less than or equal to 350 mg\u002FdL\n10. Minimum of 4 weeks since any major surgery, completion of radiation, and adequately recovered from the acute toxicities of any prior therapy, including neuropathy, to Grade ≤1\n11. Male or non-pregnant and non-breastfeeding female:\n\n    1. Females of childbearing potential must agree to use effective contraception or abstinence without interruption from 28 days prior to starting study medication throughout 3 months after last dose of study medication and have a negative serum pregnancy test (beta human chorionic gonadotropin \\[β-hCG\\]) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the EOS treatment. A second form of birth control is required even if she has had a tubal ligation.\n    2. Male patients must agree not to donate sperm and must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after last dose of study medication. A second form of birth control is required even if he has undergone a successful vasectomy.\n    3. Sexual abstinence is considered a highly effective contraceptive method only if defined as refraining from heterosexual intercourse from 28 days prior to starting study medication throughout 3 months after last dose of study medication. The reliability of sexual abstinence should be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient.\n12. The patient or the patient's legal guardian(s) understand(s) and sign(s) the informed consent\n13. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures\n14. Patients with a known history of human immunodeficiency virus (HIV) infection are eligible if:\n\n    1. There has been no acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection in 12 months prior to enrollment.\n    2. The patient has been receiving an antiretroviral therapy regimen for ≥4 weeks and the HIV viral load is \\\u003C400 copies\u002FmL prior to enrollment.\n    3. Antiretroviral therapy regimen does not include strong cytochrome (CYP)3A4 inhibitors or inducers\n\nExclusion Criteria:\n\n1. Prior treatment with mTOR inhibitors including nab-sirolimus\n\n   Note: Patients who have previously received locoregional or liver-directed therapies (radiofrequency or microwave ablation, transarterial chemoembolization, etc.) are eligible to enroll in the study.\n2. Patients with functional NETs who are experiencing uncontrolled symptoms attributed to hormones and other vasoactive substances secreted by the tumor\n3. Patients with inactivating TSC1 or TSC2 alterations (based on tissue or liquid NGS)\n4. Severe (Grade ≥3) ongoing infection requiring parenteral or oral anti-infective treatment, either ongoing or completed ≤7 days prior to enrollment\n5. Patients who have any severe and\u002For uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including:\n\n   1. Known or suspected brain metastases\n   2. Severe heart disease defined as unstable angina pectoris, NYHA Class III or IV congestive heart failure, myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.\n   3. Severe lung disease defined as a diffusing capacity for carbon monoxide that is ≤50% of normal predicted value and\u002For an O2 saturation ≤88% at rest on room air\n\n      (Note: Spirometry and pulmonary function tests are not required to be performed unless clinically indicated.)\n   4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy\n   5. A history of malignancies other than the one under treatment unless the patient is disease-free for more than 5 years from diagnosis. Controlled non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, certain low-grade hematologic malignancies (eg, chronic lymphocytic leukemia, follicular lymphoma, etc), or other adequately treated carcinoma in situ may be eligible, after discussion with the medical monitor.\n   6. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg)\n   7. Patients with history of interstitial lung disease and\u002For pneumonitis, or pulmonary hypertension\n   8. Active Hepatitis B and\u002For Hepatitis C infection and detectable viral load despite antiviral therapy.\n6. Required use of concomitant medications with strong CYP3A4 interactions (induction or inhibition) should be discontinued (strong inhibitors include ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, telithromycin; strong inducers include rifampin and rifabutin). These agents must be discontinued prior to first dose of nab-sirolimus.",{"count":83,"type":20},21,[23],"A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors",[87,88,89,90,91],"Neuroendocrine Tumors","NET","Pancreatic Neuroendocrine Tumor","Gastrointestinal Neuroendocrine Tumor","Pulmonary Neuroendocrine Tumor",[34,93,38,87,88,89,90,91],"nab-sirolimus","2024-07-15",{"date":96,"type":44},"2024-07-16",{"date":98,"type":44},"2023-11-07",{"date":100,"type":20},"2025-12-08",{"name":50,"class":51},4,""]